UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2007
Panacos Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-24241 | 11-3238476 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
134 Coolidge Avenue
Watertown, Massachusetts 02472
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (617) 926-1551
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 2.02 | RESULTS OF OPERATIONS AND FINANCIAL CONDITION |
On July 31, 2007, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced its financial results for the quarter ended June 30, 2007. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Form 8-K related to the financial results for the quarter ended June 30, 2007 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| ITEM 8.01 | OTHER EVENTS |
Panacos also announced the following items in the press release dated July 31, 2007:
| • | the beginning of Phase 1 clinical testing of bevirimat in healthy volunteers to evaluate two novel liquid formulations of bevirimat that may be suitable for long-term dosing; |
| • | the completion of a bevirimat “site of absorption” study in humans; and |
| • | the completion of the Company’s Phase 1 clinical study of PA-040, the first of its second generation maturation inhibitors designed to target bevirimat-resistant strains of HIV observed during in vitro studies. |
The information contained therein regarding the above items is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
(d) Exhibits.
| Exhibit No. | Exhibit | |
| 99.1 | Press release of Panacos Pharmaceuticals, Inc. dated July 31, 2007, announcing financial results for the quarter ended June 30, 2007. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PANACOS PHARMACEUTICALS, INC. | ||||
| Dated: July 31, 2007 |
By: | /s/ Peyton J. Marshall | ||
| Peyton J. Marshall, Ph.D. Executive Vice President and Chief Financial Officer | ||||
EXHIBIT INDEX
| Exhibit No. |
Exhibit | |
| 99.1 |
Press release of Panacos Pharmaceuticals, Inc. dated July 31, 2007, announcing financial results for the quarter ended June 30, 2007. |